HeartSciences Inc(HSCS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.2 | Insider Own | 16.6% | Shs Outstand | 5.0M | Perf Week | -5.97% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 28.86% | Insider Trans | - | Shs Float | 4.1M | Perf Month | -30.47% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.62 | Inst Own | 3.09% | Short Float | 1.53% | Perf Quarter | 43.75% |
| Income | -0.01B | P/S | - | EPS this Y | 25.9% | Inst Trans | -7.67% | Short Ratio | 0.39 | Perf Half Y | 46.57% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -201.67% | Short Interest | 0.06M | Perf YTD | -3.24% |
| Book/sh | -0.52 | P/C | 495.32 | EPS past 3/5Y | 64.81% 32.51% | ROE | -1851.9% | 52W High | -43.05% ($5.25) | Perf Year | -1.97% |
| Cash/sh | 0.01 | P/FCF | - | Sales past 3/5Y | -5.7% -29.95% | ROIC | - | 52W Low | 83.44% ($1.63) | Perf 3Y | -85.84% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 61.44% | Gross Margin | -2908.87% | Volatility(W/M) | 9.7% 10.25% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -27.7% | Oper. Margin | -209733.08% | ATR (14) | 0.37 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.05 | EPS Q/Q | 45.16% | Profit Margin | -227024.23% | RSI (14) | 42.51 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.12 | Sales Q/Q | 10.53% | SMA20 | -7.86% ($3.25) | Beta | 1.81 | Target Price | $12 |
| Payout | - | Debt/Eq | - | Earnings | 2026/9/16 | SMA50 | -17.16% ($3.61) | Rel Volume | 0.43 | Prev Close | $3.31 |
| Employees | 14 | LT Debt/Eq | - | EPS/Sales Surpr. | -19.44% - | SMA200 | 10.12% ($2.72) | Avg Volume(3M) | 0.16M | Price | $2.99 |
| IPO | 2022/6/15 | Option/Short | No/Yes | Trades | 263 | Volume | 69,925 | Change | -9.67% |
HeartSciences() is a medical device company headquartered in Southlake, Texas, USA. It develops MyoVista wavECG, an AI-based electrocardiogram (ECG) diagnostic technology. The company combines a standard 12-lead ECG with a neural network algorithm to help detect cardiac functional abnormalities such as heart failure at an early stage, and it operates as a micro-cap healthcare company.
Over the past 1 year, roughly in the middle
43% below its 1-year high.
Traded less than usual. That is 43% of its average volume.
HSCS has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +25.9% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 3 years ago, your return today would be -85.8%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 3.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #113 of 140 in the industry
Based on market cap of $15M.
PAVM#112 PAVmed Inc $15M PER - HSCS#113 HeartSciences Inc $15M PER - 
PLSM#114 Pulsenmore Ltd $13M PER - 
CTSO#115 Cytosorbents Corp $13M PER - 
SINT#116 SINTX Technologies Inc $13M PER - 
FAQ
What kind of company is HSCS?
HSCS belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of HSCS?
The market cap of HSCS is approximately $15M, ranking 5,306 within its sector.
What is the 52-week high and low for HSCS?
HSCS has recorded a 52-week high of $5.25 and a low of $1.63.
